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T aim of the present study was to compare,
during the pollen season, serum levels of total
IgE and soluble CD2 (sCD2) from patients with
allergic bronchial asthma, with those from
healthy subjects. Significantly higher levels of
total IgE and sCD23 were found in patients with
asthma compared to the control group. Both in
normal controls and in asthmatic patients, a sig-
nificant correlation was shown between the
levels of these two molecules. In asthmatic
patients, significant correlations were found for
both total IgE and sCD23, with lung function
measured as bronchial responsiveness to inhaled
methacholine. These results suggest that in asth-
matic patients, in addition to the study of total
serum IgE levels, the assessment of sCD2 serum
levels may be helpful in the evaluation of disease
activity.
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Introduction
It is well known that serum IgE levels are
elevated in patients who suffer from atopic
diseases.1’2 Furthermore, in atopic asthma, IgE
levels are recognized as a major risk factor for a
variety of respiratory symptoms.
3 From both clin-
ical and experimental evidence, asthma is now
viewed as an inflammatory airway disease invol-
ving lymphocyte activation and the release of
proinflammatory cytokines.4-7 T-cells control IgE
production by B-cells and activate nonspecific
effector cells.4’6-s In atopic individuals, stimula-
tion by allergens determines an increased synth-
esis of IgE and the up-regulation of CD23, i.e. the
low affinity receptor for IgE (FcsRII), on a variety
of cell tvoes and its release as a soluble molecule (sCD25.l The FcRIVCD23 is expressed not
only on B-lymphocytes but also on T-lympho-
cytes, monocytes, platelets and eosinophils, which
may play a role in triggering IgE-mediated effector
function.9-12 This molecule, which is a member
of the C-type animal lectin family, has been
suggested to play a role in the regulation of IgE
9-12 1-3 synthesis. As mentioned previously, this
membrane molecule may be transformed into a
soluble form by limited proteolysis, i.e. shedding,
as well as the cytokine and growth factor recep-
tors and can then be detected in biological fluids,
including serum.4 Previous studies in adults with
hyper-IgE syndrome have shown elevated serum
levels of sCD23.
5 On the other hand, sCD23 has
been suggested to be potentially useful in the
diagnosis of atopic disease.16
(C) 1996 Rapid Science Publishers
A number of investigations have considered
the association between atopic asthma and non-
specific bronchial responsiveness. The majority
of those carried out, especially those employing
histamine and methacholine tests to measure
nonspecific bronchial responsiveness, have
shown a significant association, when atopy.was
defined by an upper serum total IgE level,r> 9
In this report, to gain insight into the sig-
nificanc of serum sCD23 in asthmatic patients,
we have studied the serum levels of total IgE and
sCD23 and the relationship between these vari-
ables in asthmatic patients with regard to their
clinical status measured as bronchial responsive-
ness to inhaled methacholine.
Patients and Methods
Sample population: Thirty-five subjects were
studied; 25 were patients with bronchial asthma
(15 women and ten men, range 19-54 years). All
patients had Parietaria sensitization and a base-
line forced expiratory volume in 1 s (FEV) of at
least 80% of predicted value, a provocative con-
centration of inhaled methacholine causing a
20% fall in FEV1 (PC20) < 4000btg/ml. All
patients studied used inhaled bronchodilatators
when needed and had not been treated with dis-
odium cromoglycate in the preceding 7 days.
None of the patients was using oral or inhaled
corticosteroids. Inhaled bronchodilator therapy
was withheld for 12 h before the study. The con-
trols consisted of ten healthy women (range 18-
40 years). None of these subjects had a history
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of prolonged disease and none was ill or taking Table 1. Serum levels (mean + S.D.) of total IgE and soluble
CD23 in ten normal controls and 25 asthmatic patients any drug at the time of the study. The patients
and the control group were studied during the Healthy subjects Patients
Parietaria pollen season.
Total IgE 87.0 + 19.4 190.0 ___
45.8
sCD23 84.4 + 29.7 423.6 _+ 150.8
Quantitation of serum total IgE: IgE levels in
sera were quantitated by Phadebas IgE PRIST(R) s. b: sa.
(Pharmacia, Uppsala, Sweden). Anti-IgE antibody, < 0.00.
covalently coupled to a paper disc, was allowed
to react with the IgE in standards and sera sCD23 in the pathogenesis of airway obstruction,
during the first incubation. After washing, 1251- the blood concentrations of these products were
labelled anti-IgE antibody was added. After correlated with changes in the objective measure-
washing, the radioactivity was measured by using ments of bronchial hyperreactivity. Figs 2a and
a gamma counter. The amount of IgE was deter- 2b, respectively, demonstrate that bronchial
mined from the standard curve and expressed as responsiveness (measured as the response to
UI/ml. inhaled methacholine) significandy correlated
with total IgE and sCD23 serum levels.
Soluble CD23 assay: Serum sCD23 levels were
measured by a sandwich enzyme-linked immu- Discussion noassay (Cellfree CD23 Test-Kit-Cell Sciences,
Cambridge, MA, USA). Standards and samples Allergic processes are complex disorders in
were performed in duplicate. Absorbance was which inflammato.ry and immunological mechan-
isms are involved. CD23 is an activation marker measured at 492nm. The test was performed
4
according to the manufacturer’s instructions, expressed on B-cells as they undergo isotype
switching, and it acts as a low-affinity IgE recep-
Lung function measurements: FEV1 was mea- tor. The role of the FcRII may well relate to the
sured with a Gould 2400 (Gould, Holland) auto- cell type on which it is expressed. Accordingly,
mated system, taking the highest of three the FceRII on monocytes, platelets and eosino-
successive measurements, provided the differ- phils mediated IgE-dependent cytotoxicity and/or
ence between measurements was within 100ml. promotes phagocytosis of IgE-coated particles.
A methacholine challenge was performed accord- Concerning B-cells, the newest function pro-
ing to the method of Chai et al.
2 Increased con- .posed is enhancement of antigen processing by
centrations were administered with a Mefar nonspecific uptake of antigen IgE complexes by
(Markos, Monza, Italy) nebulizer. After baseline B-cells, that culminates in the highly efficient pre-
measurements of FEV, subjects inhaled five sentation of antigen fragments to histocompati-
puffs of saline, since that was considered as the bile, cognate T-cells. However, modulation of
control. Subjects then inhaled increasing con- CD23 expression by cytokines and correlation of
centrations of methacholine, ranging from 16 to that modulation with IgE synthesis has been
1 024 gg/ml. FEV was measured 90s after each described. Accordingly, early studies demon-
concentration step. The provocation was termi- strated that elevated IgE levels were associated
nated when FEV fell by at least 20% from the with elevated CD23 levels on B-cells. Although it
post-saline value, is now clear that interleukin-4 (IL-4) was also
involved in this up-regulation, other in vitro
Statistical analysis: All data were expressed as studies demonstrated that IgE alone was suffi-
means ___
S.D. Correlations were calculated by cient for CD23 up-regulation on lymphocytes,
linear regression. The values for the different monocytes and eosinophils by protecting CD23
groups were compared with Student’s test. from degradation into sCD23. Thus interest in
CD23 upregulation has centred largely on IL-4,
Results primarily because this cytokine directly causes
both IgE production and CD23 upregulation by
Patients with allergic asthma had significantly increasing CD23 synthesis rates.8-12’21
higher serum levels of total IgE and of sCD23 CD23 is a labile protein in that a soluble frag-
than did the normal controls (Table 1). Both in ment (sCD23) is released from cells. Previous
normal controls (Fig. la) and in asthmatic work has found sCD23 levels in patients suffer-
patients (Fig. lb), a significant correlation was ing from rhinitis, asthma and nonallergic
shown between the levels of these two mole- asthma.
22 Studies in humans have found that
cules, sCD23 potentiates IgE synthesis although the
To assess the role played by total IgE and manner is not known. Furthermore it has been
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FIG. 1. (a) Correlation between total serum IgE values (Ul/ml) and serum levels of sCD23 (U/ml) in ten normal controls (r=0.91
p=O.O002). (b) Correlation between total serum IgE values (Ul/ml) and serum levels of sCD23 (U/ml) in 25 asthmatic patients
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FIG. 2. (a) Correlation between total IgE values (Ul/ml) and inhaled concentration of methacholine (MCh) (lg/ml) that determined the
FEV1 fell by at least 20% from post-saline value (see Patients and Methods) in 25 asthmatic patients (r -0.49; p < 0.0001). (b) Cor-
relation between sCD23 values (U/ml) and inhaled concentration of methacholine (MCh) (lg/ml) that determined the FEV1 fell at least
20% from post-saline value (see Patients and Methods)in 25 asthmatic patients (r -0.43; p--O.O001).
claimed that sCD23 works as an autocrine B-cell
growth factor and it plays a role as a macrophage
inhibitory factor on monocytes. Soluble CD23
can now be acknowledged as an important
pleiotropic cytokine. In fact, it has been recently
shown to promote the differentiation of germinal
centre B-cells, early thymocytes and early myeloid
precursor cells. Besides culturing small, resting
lymphocytes with soluble CD23, the molecule
induces the synthesis of IgE in vitro when T-cells
are present. In particular, IL-4 increases the pre-
cursor frequency of IgE-producing B-cells,
whereas sCD23 induces IgE-committed B-cells to
secrete relatively larger amounts of IgE.8-12’21
In our work, differences in sCD23 levels have
been found in patients suffering from allergic
asthma during the pollen season and in non-
atopic patients. The serum total IgE levels were
clearly higher in atopic patients, as classically
established.;’ Our data show then that both in
normal controls and in asthmatic patients there is
a significant correlation between the levels of IgE
and sCD23. As discussed above, this close corre-
lation is likely mediated by IL-4 since high levels
of IgE per se do not increase serum levels. Since
previous studies have demonstrated a significant
association between allergic asthma and non-
specific bronchial responsiveness when atopy
was defined by serum total IgE,
;v-;9 we have
investigated the relationship between sCD23,
total IgE and bronchial responsiveness. The
results demonstrate that the blood concentra-
tions of both products negatively correlated with
changes in the objective measurements of bron-
chial hyperreactivity, measured as response to
inhaled methacholine, confirming and extending
previous reports.
;9
Asthma is a chronic inflammatory disorder of
the airways, in which lymphocyte activation and
the release of proinflammatory cytokines play a
role. Bronchial hyperreslonsiveness is a promi-
nent feature in asthma.4-’7 Evaluation of immune
activation is of potential value in monitoring
patients with bronchial asthma. Our results
suggest that in patients with asthma sCD23 may
be helpful in the assessment of disease activity.
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Future studies should determine the usefulness
of monitoring sCD23 levels in individual patients
with bronchial asthma for the prediction of the
bronchial hyperresponsiveness and imminent
broncho-obstruction.
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